Table 1. Baseline characteristics of 0.2 μg/day FAc-treated patients by lens status and duration of DMO.
|
Pseudophakic at baseline (CBI group) |
Phakic→pseudophakic (CAI group) |
|||
|---|---|---|---|---|
| Chronic DMO (n=95) | Nonchronic DMO (n=44) | Chronic DMO (n=97) | Nonchronic DMO (n=91) | |
| BCVA, mean (SE), ETDRS letters | 52.5 (1.40) | 53.3 (2.00) | 51.6 (1.33) | 54.7 (1.19) |
| Centre point thickness, mean (SE), μm | 448.0 (17.45) | 490.0 (22.59) | 462.0 (17.11) | 463.2 (16.43) |
| Duration of diabetes, mean (SE), y | 19.7 (0.98) | 18.2 (1.54) | 17.2 (0.93) | 15.0 (0.91) |
| Duration of DMO, mean (SE), y | 5.1 (0.31) | 1.6 (0.08) | 5.2 (0.33) | 1.7 (0.05) |
| Diabetes type, n (%) | ||||
| Type 1 | 8 (8.4) | 3 (6.8) | 9 (9.3) | 4 (4.4) |
| Type 2 | 85 (89.5) | 41 (93.2) | 85 (87.6) | 86 (94.5) |
| Uncertain | 2 (2.1) | 0 | 3 (3.1) | 1 (1.1) |
| HbA1c, mean (SE), % | 7.6 (0.16) | 7.8 (0.17) | 7.9 (0.17) | 7.9 (0.19) |
Abbreviations: BCVA, best corrected visual acuity; CAI, cataract (surgery) after implant; CBI, cataract (surgery) before implant; DMO, diabetic macular oedema; ETDRS, Early Treatment Diabetic Retinopathy Study; FAc, fluocinolone acetonide; HbA1c, glycosylated haemoglobin; SE, standard error.